CorVel/$CRVL
1D1W1MYTD1Y5YMAX
Capital at risk
About CorVel
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
- Ticker
- $CRVL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 5,239
- Headquarters
- Fort Worth, United States
- Website
- www.corvel.com
CorVel Metrics
BasicAdvanced
$3.6B
31.67
$2.25
0.95
-
Price and volume
Market cap
$3.6B
Beta
0.95
52-week high
$83.92
52-week low
$44.83
Average daily volume
187K
Financial strength
Current ratio
1.941
Quick ratio
1.411
Long term debt to equity
0.051
Total debt to equity
0.069
Profitability
EBITDA (TTM)
184.128
Gross margin (TTM)
24.79%
Net profit margin (TTM)
11.72%
Operating margin (TTM)
15.37%
Effective tax rate (TTM)
23.72%
Revenue per employee (TTM)
$190,000
Management effectiveness
Return on assets (TTM)
14.68%
Return on equity (TTM)
30.70%
Valuation
Price to earnings (TTM)
31.667
Price to revenue (TTM)
3.703
Price to book
8.81
Price to tangible book (TTM)
9.69
Price to free cash flow (TTM)
32.008
Free cash flow yield (TTM)
3.12%
Free cash flow per share (TTM)
2.225
Growth
Revenue change (TTM)
7.09%
Earnings per share change (TTM)
16.55%
3-year revenue growth (CAGR)
10.33%
10-year revenue growth (CAGR)
6.89%
3-year earnings per share growth (CAGR)
19.35%
10-year earnings per share growth (CAGR)
16.46%
Bulls say / Bears say
CorVel’s June-quarter revenue rose 11% year on year to $260 million, while diluted EPS increased 21% to $0.63 and gross profit rose 19%. The simultaneous growth in sales and margin supports the case for improving operating leverage. (GlobeNewswire)
CorVel reported multiple large payer wins, including two new multi-year partnerships with top-ten national payers, and plans to launch four large payer programmes in 2026. If implementations scale as expected, they could provide a clearer growth path for its payment-integrity business. (The Motley Fool)
CorVel is embedding AI into claims workflows through CorVel Connected, with tools for real-time insight, claim summarisation and decision support, while also adding market-based medical-bill repricing. Broader workflow adoption could improve productivity and strengthen the value of its integrated platform. (BioSpace, GlobeNewswire)
Workers’ compensation faces rising claim complexity and medical-cost inflation, while health plans face margin compression and tighter regulation. These pressures could make clients more price-sensitive and limit CorVel’s margin gains. (Seeking Alpha)
CorVel operates under differing state licensing and regulatory regimes, and its annual report warns that customers may terminate contracts or be acquired. Compliance demands and client churn could make revenue and costs less predictable. (MarketScreener)
June-quarter EPS included an estimated $0.07 per share benefit from a legacy accounts-receivable settlement. That one-off gain makes the 21% headline EPS increase less representative of the underlying run rate. (Stock Observer)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
CorVel Financial Performance
Revenues and expenses
Upcoming events
No upcoming events
CorVel News
AllArticlesVideos
Funds containing CorVel
AllUSDEURGBP
Fund name | Fund size | $CRVL weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.22% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.22% |
iShares Healthcare Innovation£DRDR | £1B | 0.22% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.13% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.